Intuitive Surgical, Inc. (NASDAQ: ISRG) is a medical-device company best known for its da Vinci robotic-assisted surgery system and its Ion platform for minimally invasive lung biopsy. The central $480 target in this article is not a single analyst's call; it is the rounded arithmetic mean of the current analyst price targets surveyed by S&P Global, which put the average near $478.53 across roughly 34 analysts. Because the mean sits comfortably more than 10% above the latest price, it serves as the central target.
The dispersion among individual targets is wide. On the cautious side, HSBC set a $391 target with a Hold rating, and Mizuho holds a $415 target. Barclays initiated coverage with an Overweight rating and a $485 target, while Oppenheimer moved to Outperform with a $500 target. UBS reiterated a Buy at $500, RBC Capital reaffirmed a Buy at $575, and Bernstein's target of roughly $685 anchors the top of the range. Recent revisions have leaned lower: BTIG trimmed its target to $454 from $469, and BofA reduced its target in several steps. The wide $324-to-$685 range underscores that analysts broadly agree on Intuitive's long-term franchise but disagree sharply on how much premium the market should pay now.
With shares around $427, the move to $480 represents an upside of roughly 12%, which qualifies as a modest climb in percentage terms. The stock has been volatile: it peaked above $600 in January 2026 and has fallen roughly 24% to 29% year to date, before rebounding meaningfully over recent months.
Fundamentals remain robust. In the second quarter of 2026, Intuitive reported revenue of about $2.89 billion, up roughly 19% year over year, with adjusted EPS (earnings per share) of $2.80 beating the consensus estimate of $2.48. Worldwide da Vinci and Ion procedures grew approximately 16%, and the company guided to full-year da Vinci procedure growth of 13.5% to 15.5%. Recurring revenue from instruments, accessories, and services represents roughly 84% to 86% of sales, giving the business a predictable, high-margin core.
Several factors could help the stock trend toward $480. The installed base of da Vinci systems grew about 12% year over year to more than 11,700 units, and the newer da Vinci 5 platform is commanding higher prices and driving faster instrument revenue per procedure. The Ion lung-biopsy platform is growing even more quickly, with procedures up roughly 36% year over year. Intuitive is also investing in artificial intelligence, software, and new clinical indications, which could widen its addressable market over time. A landmark meta-analysis covering more than 14 million procedures recently reported improved outcomes with da Vinci surgery across 13 conditions, strengthening the clinical case for adoption. Aging demographics in the U.S., Europe, and Asia provide a durable secular tailwind for minimally invasive surgery.
The principal obstacle is valuation. Even after the decline, Intuitive trades at a forward P/E (price-to-earnings ratio) in the mid-30s, well above most mature medical-device peers, leaving little room for disappointment. Slowing procedure growth is a real concern: management acknowledged a high-single-digit decline in U.S. bariatric cases as GLP-1 weight-loss drugs reduce demand, and the expiration of certain Affordable Care Act subsidies created modest pressure. Competition is intensifying, with Johnson & Johnson's FDA-cleared OTTAVA system, Medtronic's Hugo platform, and domestic rivals in China all competing for share. Tariffs and higher freight and memory costs are also expected to pressure gross margin by about one percentage point in 2026.
The stock's January peak above $600 now stands as a meaningful resistance area far above the $480 target, while the $480 level itself sits just above a cluster of recent analyst targets in the $454-to$485 range. On the downside, the stock's 2026 lows in the $340-to$350 zone represent a broader support region, with the psychologically important $400 level in between. The recent rebound from those lows suggests improving momentum, but the stock remains below its 2026 highs, and any failure to hold near current levels could keep it range-bound rather than trending toward the analyst average.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual analysts may use different periods. Key items to watch include Intuitive's quarterly earnings (the next report follows the October 20 date), procedure-growth trends versus the 13.5%-to-15.5% guidance, the pace of da Vinci 5 placements, and any updates on competition from Johnson & Johnson's OTTAVA. Investors should also monitor analyst revisions, which have been drifting lower, and broader medtech valuation sentiment, which has been a significant driver of the stock's 2026 performance.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like ISRG, where analyst views are split and valuation swings can be sharp, such signals can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently. Explore AI Daily Buy/Sell Signals to see how AI-powered insights can support your market analysis.
The $480 central target is a calculated average of current analyst price targets, not a prediction, and it implies only a modest, roughly 12% advance from the latest price near $427. The supporting case rests on durable double-digit procedure growth, an expanding installed base, and a high-margin recurring-revenue model. The opposing case rests on a premium valuation, moderating procedure growth from GLP-1 drugs, and a more competitive landscape. With targets spread from about $324 to $685, the range itself is the clearest signal that Wall Street has not settled on where Intuitive should trade. Whether the stock reaches $480 will likely depend less on any single quarter and more on whether procedure growth, margins, and competitive dynamics support the premium multiple the market currently assigns.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | +1.12% | ||
| BSX - ISRG | 73% Closely correlated | +5.57% | ||
| SYK - ISRG | 64% Loosely correlated | +5.12% | ||
| NTRA - ISRG | 54% Loosely correlated | -8.54% | ||
| GKOS - ISRG | 51% Loosely correlated | +0.43% | ||
| PODD - ISRG | 49% Loosely correlated | +2.63% | ||
More | ||||
| Ticker / NAME | Correlation To ISRG | 1D Price Change % |
|---|---|---|
| ISRG | 100% | +1.12% |
| ISRG (2 stocks) | 99% Closely correlated | -0.49% |
| Pharmaceuticals: Other (49 stocks) | 61% Loosely correlated | +0.27% |
| Pharmaceuticals (153 stocks) | 6% Poorly correlated | +0.67% |